229 related articles for article (PubMed ID: 31043459)
1. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
2. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
[TBL] [Abstract][Full Text] [Related]
3. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
4. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
[TBL] [Abstract][Full Text] [Related]
6. Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.
Wang Z; Chen J; Wang J; Ahn S; Li CM; Lu Y; Loveless VS; Dalton JT; Miller DD; Li W
Pharm Res; 2012 Nov; 29(11):3040-52. PubMed ID: 22410804
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
8. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
9. SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines.
Yan W; Yang T; Yang J; Wang T; Yu Y; Wang Y; Chen Q; Bai P; Li D; Ye H; Qiu Q; Zhou Y; Hu Y; Yang S; Wei Y; Li W; Chen L
Cell Physiol Biochem; 2018; 47(2):489-504. PubMed ID: 29794416
[TBL] [Abstract][Full Text] [Related]
10. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
Boichuk S; Galembikova A; Syuzov K; Dunaev P; Bikinieva F; Aukhadieva A; Zykova S; Igidov N; Gankova K; Novikova M; Kopnin P
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641324
[TBL] [Abstract][Full Text] [Related]
11. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
Mahmud F; Deng S; Chen H; Miller DD; Li W
Cancer Lett; 2020 Dec; 495():76-88. PubMed ID: 32920198
[TBL] [Abstract][Full Text] [Related]
12. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
[TBL] [Abstract][Full Text] [Related]
13. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.
Zheng YB; Gong JH; Liu XJ; Wu SY; Li Y; Xu XD; Shang BY; Zhou JM; Zhu ZL; Si SY; Zhen YS
Sci Rep; 2016 Aug; 6():31472. PubMed ID: 27510727
[TBL] [Abstract][Full Text] [Related]
14. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
15. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
[TBL] [Abstract][Full Text] [Related]
16. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L
Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.
Lin S; Du T; Zhang J; Wu D; Tian H; Zhang K; Jiang L; Lu D; Sheng L; Li Y; Ji M; Chen X; Xu H
J Med Chem; 2022 Dec; 65(24):16372-16391. PubMed ID: 36511661
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and bioevaluation of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazoles as tubulin polymerization inhibitors.
Liu R; Huang M; Zhang S; Li L; Li M; Sun J; Wu L; Guan Q; Zhang W
Eur J Med Chem; 2021 Dec; 226():113826. PubMed ID: 34571171
[TBL] [Abstract][Full Text] [Related]
20. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
Deng S; Banerjee S; Chen H; Pochampally S; Wang Y; Yun MK; White SW; Parmar K; Meibohm B; Hartman KL; Wu Z; Miller DD; Li W
Cancer Lett; 2023 Feb; 555():216046. PubMed ID: 36596380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
